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Dear Editor,
Colistin is the last line of defense for carbapenem-resistant En-
terobacteriaceae (CRE) or Acinetobacter baumannii infection 
[1]. Recently, a plasmid-mediated colistin resistance mecha-
nism (mcr-1 gene) was identified in human, animal, and envi-
ronmental isolates in China, and the worldwide spread of the 
mcr-1 gene has continuously been reported [2]. This colistin re-
sistance mechanism has mainly been found in isolates linked to 
community-associated infections or from animals [2]. However, 
mcr-1-encoding plasmid-mediated colistin-resistant Escherichia 
coli isolates were detected in a Danish patient with a bloodstream 
infection [3]. This possibility raises major public health concern 
for the emerging threats of CRE, given the limited therapeutic 
options, clinical severity, and poor outcomes. The aim of this study 
was to evaluate the recent epidemiology of colistin resistance in 
bloodstream E. coli, including mcr-1-mediated colistin resistance 
in Korea. 
Clinical non-duplicated E. coli isolates (n=1,193), included in 
this study, were previously isolated from the blood of patients and 
stored in skim milk at -70°C until the tests at a tertiary teaching 
hospital in Seoul, Korea during 2014–2015. To detect colistin-
resistant isolates, test organisms were screened on Mueller-Hin-
ton agar (Oxoid, Basingstoke, UK) containing colistin (0, 1, 2, 
and 4 μg/mL) with the E. coli ATCC25922 strain. One isolate was 
grown on an agar plate with a concentration of 4 μg/mL colistin 
and the minimal inhibitory concentration (MIC) of colistin, deter-
mined by E-test (bioMérieux, Marcy l’E’toile, France) was 6 μg/
mL, indicating that the isolate was resistant to colistin, according 
to the EUCAST resistance criteria (>2 μg/mL) [4]. The mcr-1 
gene was not detected following repeated PCR in this isolate [2]. 
The overall prevalence of colistin resistance in E. coli isolates 
from the blood was 0.15% (1/644) in 2015 and 0% (0/549) in 
2014. 
In this study, only one isolate was found to be resistant to co-
listin, but the resistance was not conferred by the mcr-1 gene. 
Although the mechanism underlying resistance in this isolate is 
currently unclear, lipopolysaccharide (LPS) modification via di-
verse routes is a well-known mechanism of colistin-resistance in 
Gram negative bacilli, and polymyxin-resistant mutants of E. coli 
show a higher rate of substitution of the ester-linked phosphate 
group in the lipid A portion of LPS [5]. Other possible colistin re-
sistance mechanisms are overexpression of efflux pump systems 
and overproduction of the capsule polysaccharide [5]. 
In conclusion, the prevalence of colistin resistance in E. coli 
isolates from the blood of patients with bloodstream infection in 
Korea was very low, and the mcr-1 gene was not detected. Co-
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listin susceptibility appears to be well conserved in E. coli caus-
ing blood-stream infections in Korea. However, the incidence of 
community-associated E. coli bacteremia continues to rise in 
Korea [6]. Therefore, the inflow of plasmid-mediated colistin via 
the mcr-1 gene should be closely monitored in E. coli blood iso-
lates. 
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